The fact that their continued success with these systems has resulted in this expansion of their capabilities really speaks to the power these solutions offer our customers.
Sunnyvale, CA (PRWEB) October 14, 2014
Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced that the U.S. Department of Energy’s Pacific Northwest National Laboratory (PNNL) acquired a Freeslate Core Module 3 (CM3) Reaction Screening System and Screening Pressure Reactor to expand its high throughput research capabilities for catalyst screening and optimization. Addition of these high throughput instruments allows a wider range of test parameters to be studied in the area of catalysis, materials, and energy, focusing on biomass conversion and alternative energy.
The new Freeslate solutions will be fully integrated into existing Freeslate workflows and utilized by The Institute of Interfacial Catalysis. The instrumentation will be housed in the Bioproducts, Sciences and Engineering Laboratory (BSEL). BSEL is a multipurpose research and development facility that advances the science, engineering, and processes for bio-based products. BSEL is located on the Washington State University Tri-Cities Campus in Richland, WA, one mile south of the main PNNL campus.
“We are very pleased with our continued relationship with Pacific Northwest National Laboratory” commented John S. Senaldi, President and CEO of Freeslate. “They began work in the area of high throughput in 2002, and first purchased Freeslate systems back in 2009. The fact that their continued success with these systems has resulted in this expansion of their capabilities really speaks to the power these solutions offer our customers.”
Freeslate products are designed to accelerate innovation by screening a broader experimental space with hundreds of catalysts, limiting simplifying assumptions, and delivering non-intuitive results. Freeslate offers unique, high throughput solutions for screening chemical reactions including automated powder dispensing systems, automated reaction screening systems, high throughput high pressure reactors, and a powerful data management suite for getting the most out of the data generated.
Freeslate is a privately held company providing laboratory automation products that dramatically improve the productivity and innovation of drug development organizations. For more than a decade, Freeslate has been working with customers to automate complex chemical research processes. Our resulting product line includes solutions for protein and vaccine drug formulation development, small molecule solubility, and polymorph screening and process chemistry. We start with a scientific understanding of our customer’s bottlenecks and utilize our robust and proprietary automation platforms and integrated Lab Execution and Analysis (LEA) software suite to deliver solutions that make a difference. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.